--- title: 'Life Sciences Daily Summary: What Happened on October 15, 2026' headline: FDA expands Anktiva’s bladder cancer use as OMass raises $310 million description: The day also brought an FDA rare-disease review initiative, Vanda’s anxiety-trial failure, Iambic’s $150 million IPO and updated UK antidepressant safety information. url: https://thebench.bio/news/summaries/2026-10-15 topic: all date: '2026-10-15' covers: - '2026-10-15' date_published: '2026-10-15T12:05:03Z' date_modified: '2026-10-15T12:05:03Z' tags: - Regulatory - Funding - Clinical - Industry sources: 11 publisher: TheBench.Bio --- # Life Sciences Daily Summary: What Happened on October 15, 2026 **FDA expands Anktiva’s bladder cancer use as OMass raises $310 million** The day also brought an FDA rare-disease review initiative, Vanda’s anxiety-trial failure, Iambic’s $150 million IPO and updated UK antidepressant safety information. ## Today in brief The FDA expanded Anktiva’s use with BCG to adults with BCG-unresponsive, high-grade papillary-only bladder cancer that hasn’t invaded the muscle. [1] [2] OMass raised $310 million to advance its drug pipeline, while Vanda paused VQW-765 after a Phase III anxiety trial missed its primary and key secondary endpoints. [3] [4] The FDA launched an initiative to review rare-disease drug development, and Iambic raised $150 million in an IPO. [5] [6] The UK regulator plans clearer antidepressant warnings and a patient leaflet in 2027. [7] ## FDA extends Anktiva to another form of bladder cancer The FDA approved Anktiva with BCG for adults with BCG-unresponsive, high-grade papillary-only bladder cancer that hasn’t invaded the muscle. [1] The agency called it the first approved treatment specifically for this group. [1] The decision drew on evidence from Anktiva’s earlier approval for bladder cancer involving carcinoma in situ, along with scientific similarities between the conditions. [1] In the earlier-approval trial, 62% of 77 adults had a complete response. Of those responders, 40% maintained it for at least 24 months. [1] Anktiva is delivered into the bladder through a catheter, initially once a week for six weeks. Further treatment depends on response. [1] The FDA is finalizing guidance on using evidence from carcinoma-in-situ studies to support applications for papillary-only disease. [1] ## OMass raises $310 million for endocrine and autoimmune programs OMass Therapeutics raised $310 million in a Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings. [3] The round brings the company’s total funding to about $475 million and is Europe’s second-largest private biotech financing of 2026, after Isomorphic’s $2.1 billion round in May. [3] OMass said it will use most of the proceeds to advance OMS1620 through Phase 2 for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. [3] The company aims to block ACTH activity at the adrenal gland, lowering androgen production while allowing reduced glucocorticoid doses. [3] OMass said the funding will also support early clinical development of an SLC15A4 inhibitor for lupus and other autoimmune diseases. [3] ## Vanda pauses VQW-765 after Phase III anxiety trial misses endpoints Vanda Pharmaceuticals paused clinical development of VQW-765 after a Phase III study missed its primary and key secondary endpoints. [4] The study found no significant effect on acute social anxiety symptoms in the female subgroup or significant anxiety reduction across the full population. [4] Vanda said it will analyze the full trial dataset while the program is paused. [4] Vanda licensed VQW-765 from Novartis in 2014 and is not currently studying it for another condition. [4] ## FDA starts work on a tailored rare-disease framework The FDA launched an initiative to review how it develops and evaluates drugs and biologics for rare diseases, with the aim of accounting for differences in diseases, patient populations and feasible evidence. [5] [8] [9] The agency plans to examine guidance, review practices, coordination among reviewers, patient input and manufacturing-quality review while retaining its safety and effectiveness standards. [9] [10] The FDA plans to begin gathering public input at an October 28 meeting, followed by roundtables and requests for information. [8] [9] Possible outcomes include new or revised guidance, regulatory changes, staff training or organizational adjustments. The agency hasn’t committed to a specific change. [9] [11] The FDA and the Department of Health and Human Services say about 5% of rare conditions have an approved treatment. [5] [11] ## MHRA adds clearer antidepressant risk information The UK Medicines and Healthcare products Regulatory Agency is updating antidepressant safety information after patients and families raised concerns about suicidal thoughts and behavior, as well as sexual dysfunction that can persist after treatment ends. [7] Medicine leaflets will get a boxed warning directing readers to information about suicidal thoughts and behavior. The regulator expects a patient card to accompany the medicines. [7] Some leaflets will also use the term Post SSRI Sexual Dysfunction for symptoms that may continue after treatment stops. [7] A separate safety leaflet for people starting or already taking antidepressants is due in 2027. [7] MHRA chief safety officer Alison Cave advised patients to consult a healthcare professional before stopping medication. [7] ## Iambic raises $150 million in IPO Iambic raised $150 million in an initial public offering. [6] Iambic said in regulatory filings that its AI drug-discovery approach could substantially change established methods. [6] ## The day in numbers - **$310 million**: OMass’s Series C financing to advance its drug pipeline. [3] - **62%**: Share of 77 adults in the trial supporting Anktiva’s earlier approval who had a complete response. [1] - **$150 million**: Amount Iambic raised in its IPO. [6] - **5%**: Share of rare conditions that the FDA says have an approved treatment. [5] [11] ## Sources 1. [FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer ](), FDA Press Announcements, 2026-10-14 2. [ImmunityBio’s bladder cancer drug, Anktiva lands US label expansion  ](), Pharmaceutical Technology, 2026-10-15 3. [OMass raises $310M in Europe’s second-largest biotech round of 2026](), European Biotechnology, 2026-10-15 4. [Vanda puts anxiety drug’s development on ice after Phase III fail ](), Clinical Trials Arena, 2026-10-15 5. [Rare disease regulation reaches “inflection point” with new FDA framework](), Pharmaceutical Technology, 2026-10-15 6. [Iambic, an AI drug discovery specialist, banks $150M in an IPO](), BioPharma Dive, 2026-10-15 7. [MHRA introduces new safeguards to strengthen antidepressant safety information following major review](), MHRA, 2026-10-15 8. [FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development](), FDA Press Announcements, 2026-10-14 9. [FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development](), BioPharm International, 2026-10-14 10. [FDA Launches Rare Disease Framework Initiative to Reimagine Drug Development for Small Patient Populations](), Applied Clinical Trials, 2026-10-14 11. [FDA Launches Rare Disease Framework Initiative](), Pharmaceutical Executive, 2026-10-14 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: [7]: [8]: [9]: [10]: [11]: